Patents by Inventor Yihan Wang

Yihan Wang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11001580
    Abstract: The invention relates to c-Kit inhibitors useful in the treatment of cancers, and other-threonine kinase mediated diseases, having the Formula: (I) wherein A, L, R1, R2, R3, and n are described herein.
    Type: Grant
    Filed: December 14, 2017
    Date of Patent: May 11, 2021
    Assignee: ARIAD PHARMACEUTICALS, INC.
    Inventors: Nicholas E. Bencivenga, David C. Dalgarno, Joseph M. Gozgit, Wei-Sheng Huang, Anna Kohlmann, Feng Li, Jiwei Qi, William C. Shakespeare, Ranny M. Thomas, Yihan Wang, Xiaotian Zhu
  • Patent number: 10995103
    Abstract: A substituted boric acid compound, a pharmaceutical composition including the same, and an application thereof. The substituted boric acid compound is a compound represented by formula (I), or a crystal form, a pharmaceutically acceptable salt, a prodrug, a stereoisomer, a hydrate, or a solvent compound thereof. The boric acid compound has proteasome inhibitory activity, good pharmacodynamic/pharmacokinetic performance, good applicability, and high safety, and can be used for preparing drugs for treating diseases related to proteasomes.
    Type: Grant
    Filed: July 24, 2017
    Date of Patent: May 4, 2021
    Assignee: Shenzhen TargetRx, Inc.
    Inventors: Yihan Wang, Jiuyang Zhao
  • Publication number: 20210107906
    Abstract: Provided are pharmaceutical compositions comprising substituted pyrazolo[1,5-a]pyrimidine compounds and the use thereof. The compositions may comprise the substituted pyrazolo[1,5-a]pyrimidine compound or a pharmaceutically acceptable salt, prodrug, hydrate or solvate, polymorph, stereoisomer or isotopic variant thereof, and can be used for treating diseases treatable with Trk kinase inhibitors.
    Type: Application
    Filed: December 18, 2018
    Publication date: April 15, 2021
    Inventors: Yihan WANG, Jiuyang ZHAO
  • Publication number: 20210094939
    Abstract: A substituted amino heterocyclic carboxamide compound as represent by formula (?), or a pharmaceutically acceptable salt, a prodrug, a hydrate or a solvent compound, a crystal form, a stereoisomer or an isotopic variant of the compound, and a pharmaceutical composition thereof, and the use thereof as an FLT3/AXL kinase inhibitor for treating acute myelocytic leukemia.
    Type: Application
    Filed: March 28, 2019
    Publication date: April 1, 2021
    Inventors: Yihan Wang, Huanyin Li
  • Publication number: 20210093650
    Abstract: The present invention relates to a compound of a novel antiviral nucleoside reverse transcriptase inhibitor, a pharmaceutical composition containing the compound, and preparation and application of the compound. Specifically, disclosed in the present invention are a fused pyrimidine compound as represented by formula (I) and a pharmaceutical composition comprising the compound, or a pharmaceutically acceptable salt, stereoisomer, solvate, hydrate, crystal form, prodrug or isotopic derivative of the compound. The compound of the present invention can be used for treatment and/or prevention of infectious diseases caused by viruses, such as human immunodeficiency virus (HIV), hepatitis B virus (HBV).
    Type: Application
    Filed: December 4, 2018
    Publication date: April 1, 2021
    Inventors: Yihan Wang, Jiuyang Zhao
  • Publication number: 20210087213
    Abstract: Disclosed are a dianilinopyrimidine compound having an inhibitory effect on protein tyrosine kinase, pharmaceutically acceptable salts, crystal forms, prodrugs, metabolites, hydrates, solvates, stereoisomers or isotopic derivatives thereof, a pharmaceutical composition containing these compounds, as well as preparation and use of these compounds. The compound has a structure as represented by formula (I), and may be used for treating ALK-mediated cancer-related symptoms, such as non-small cell lung cancer, breast cancer, nerve tumors, esophagus cancer, soft tissue cancer, lymphoma, or leukemia.
    Type: Application
    Filed: December 12, 2018
    Publication date: March 25, 2021
    Inventors: Yihan Wang, Huanyin Li
  • Publication number: 20210070758
    Abstract: A fused bicyclic compound having an effect in inhibition of the activity of a tyrosine kinase, and preparation and use thereof are disclosed. In particular, a compound of formula (I) or a pharmaceutically acceptable salt, a stereoisomer, a solvate, a hydrate, a polymorph, a prodrug or an isotopic variation thereof, as well as a pharmaceutical composition including the same are disclosed. As a selective irreversible inhibitor of Bruton's tyrosine kinase, the described compound can be used for preventing or treating diseases such as inflammation, autoimmune diseases (such as rheumatoid arthritis), xenogeneic immune diseases and cancers.
    Type: Application
    Filed: August 16, 2017
    Publication date: March 11, 2021
    Applicant: Shenzhen TargetRx. Inc.
    Inventors: Yihan Wang, Qingfeng Xing
  • Publication number: 20210046058
    Abstract: A macrocycle represented by formula (I) and a pharmaceutical composition comprising the macrocycle, or a crystalline form, pharmaceutically acceptable salt, hydrate or solvent compound, stereoisomer, prodrug, or isotopic variant of the macrocycle. The macrocycle and the composition thereof inhibit a protein kinase.
    Type: Application
    Filed: August 27, 2020
    Publication date: February 18, 2021
    Inventors: Yihan Wang, Huanyin Li
  • Publication number: 20210047330
    Abstract: Provided are a pharmaceutical composition of a substituted pyrazolo[1,5-a]pyrimidine macrocyclic compound and the use thereof. The pyrazolo[1,5-a]pyrimidine macrocyclic compound is a compound as shown in formula (Aa), or a pharmaceutically acceptable salt, a prodrug, a hydrate or a solvate, a crystal form, a stereoisomer or an isotopic variant thereof. The compound of the present invention is an inhibitor of the Trk kinase, and can be used for treating pain, cancers, inflammation, neurodegenerative diseases and certain infectious diseases.
    Type: Application
    Filed: January 23, 2019
    Publication date: February 18, 2021
    Inventors: Yihan WANG, Jiuyang ZHAO
  • Publication number: 20210045749
    Abstract: In some examples, an embolization device includes multiple sections with three-dimensional non-helical structures when deployed at a vascular site. The multiple sections include a first section and one or more second sections that are smaller than the first section. The first section may have a deployed structure configured to anchor the device at a vascular site (e.g., a blood vessel) of a patient while each of the one or more second sections may be formed from loops that configured to pack and obstruct the vascular site. In some cases, the embolization device also includes a third section having a deployed configuration with multiple helical windings or loops is configured to anchor the embolization device at the vascular site.
    Type: Application
    Filed: August 13, 2019
    Publication date: February 18, 2021
    Inventors: Yihan Wang, Victoria Schuman, Zhimin Fang, Yapeng Xu, Haitao Cao, Zhipeng Chen, Xiaojing Guo, Shichang Wen
  • Publication number: 20210040101
    Abstract: Provided in the present invention are a substituted pyrrolotriazine compound, a pharmaceutical composition thereof and a use thereof, the pyrrolotriazine compound being a compound represented by formula (?), or a pharmaceutically acceptable salt, prodrug, hydrate or solvent compound, crystalline form, stereoisomer or isotope variant thereof. The compound and composition of the present invention may be used in the treatment of conditions associated with KIT and/or PDGFR?.
    Type: Application
    Filed: April 15, 2019
    Publication date: February 11, 2021
    Inventors: Yihan WANG, Huanyin LI
  • Publication number: 20210009613
    Abstract: The present invention relates to an arylphosphine oxide having inhibitory effect on protein tyrosine kinases, a pharmaceutical composition containing the same, a preparation and a use thereof. Specifically, the present invention discloses a compound represented by formula (I), a pharmaceutically acceptable salt, crystal form, prodrug, metabolite, hydrate, solvate, stereoisomer or isotope derivative thereof, wherein X, Y, R1, RP1, RP2, R2, W and m are as defined in the description. The compound of the invention can be used in the treatment of ALK-mediated cancer-associated disorders, such as non-small cell lung cancer, breast cancer, neurological tumors, esophageal cancer, soft tissue cancer, lymphoma or leukemia.
    Type: Application
    Filed: December 10, 2018
    Publication date: January 14, 2021
    Inventors: Yihan Wang, Huanyin Li
  • Patent number: 10875853
    Abstract: Provided are a (hetero)arylamide compound as shown in formula (I) having an inhibitory effect on protein kinase activity, a pharmaceutically acceptable salt, a stereoisomer, a solvate or hydrate thereof, a pharmaceutical composition including the compound or a derivative thereof, and a method for preparing the compound. The compound can be used as an irreversible inhibitor for protein kinase, for preparing a plurality of drugs including an anti-tumour drug.
    Type: Grant
    Filed: January 19, 2018
    Date of Patent: December 29, 2020
    Assignee: Shenzhen TargetRx, Inc.
    Inventors: Yihan Wang, Jiuyang Zhao, Yixin Ai
  • Publication number: 20200377473
    Abstract: Provided are a (hetero)arylamide compound as shown in formula (I) having an inhibitory effect on protein kinase activity, a pharmaceutically acceptable salt, a stereoisomer, a solvate or hydrate thereof, a pharmaceutical composition comprising the compound or a derivative thereof, and a method for preparing the compound. The compound can be used as an irreversible inhibitor for protein kinase for preparing a plurality of drugs comprising an anti-tumour drug.
    Type: Application
    Filed: January 19, 2018
    Publication date: December 3, 2020
    Applicant: Shenzhen TargetRx, Inc.
    Inventors: Yihan WANG, Jiuyang ZHAO, Yixin AI
  • Patent number: 10851062
    Abstract: Provided in the present invention are a substituted heteroaryl compound, a composition containing same, and an application thereof, the present invention disclosing a heteroaryl compound of the formula (I), or a crystalline form, a pharmaceutically acceptable salt, a prodrug, a stereoisomer, a hydrate, or a solvent compound thereof. The substituted heteroaryl compound and the composition containing same set forth in the present invention can be used for regulating hypoxia inducible factor (HIF) and/or endogenous erythropoietin (EPO), simultaneously having better pharmacokinetic parameter characteristics and being able to improve the drug concentration of the compound in animal bodies, in order to improve the curative effect and safety of the drug.
    Type: Grant
    Filed: November 18, 2019
    Date of Patent: December 1, 2020
    Assignee: Shenzhen TargetRx, Inc.
    Inventors: Yihan Wang, Xingye Ren
  • Publication number: 20200369696
    Abstract: An antiviral nucleoside reverse transcriptase inhibitor compound as shown in formula (I), and a pharmaceutically acceptable salt, a stereoisomer, a solvate, a hydrate, a crystal form or an isotopic derivative of the compound. A preparation method therefor, a pharmaceutical composition thereof, and a use thereof in the preparation of a drug for treating and/or preventing viral infectious diseases, such as human immunodeficiency virus (HIV) and hepatitis B virus (HBV).
    Type: Application
    Filed: December 6, 2018
    Publication date: November 26, 2020
    Inventors: Yihan Wang, Jiuyang Zhao
  • Publication number: 20200347035
    Abstract: The present invention relates to a pharmaceutical composition of a substituted pyridazinone compound and use thereof. The substituted pyridazinone compound is a compound as represented by formula (I), or a pharmaceutically acceptable salt, a prodrug, a hydrate or solvent compound, a crystalline form, and a stereoisomer or isotopic variant thereof. The compound is a THR-beta agonist which can be used for treating and/or preventing diseases regulated by thyroid hormone analogues.
    Type: Application
    Filed: January 17, 2019
    Publication date: November 5, 2020
    Inventors: Yihan Wang, Zhiqiang Liu
  • Publication number: 20200317705
    Abstract: The invention features compounds of the general formula (I) in which the variable groups are as defined herein, and to their preparation and use.
    Type: Application
    Filed: November 1, 2019
    Publication date: October 8, 2020
    Inventors: Yihan Wang, Wei-Sheng Huang, Shuangying Liu, William C. Shakespeare, Ranny M. Thomas, Jiwei Qi, Feng Li, Xiaotian Zhu, Anna Kohlmann, David C. Dalgarno, Jan Antoinette C. Romero, Dong Zou
  • Patent number: 10780082
    Abstract: A macrocycle represented by formula (I) and a pharmaceutical composition including the macrocycle, or a crystalline form, pharmaceutically acceptable salt, hydrate or solvent compound, stereoisomer, prodrug, or isotopic variant of the macrocycle. The macrocycle and the composition thereof inhibit a protein kinase.
    Type: Grant
    Filed: September 10, 2019
    Date of Patent: September 22, 2020
    Assignee: Shenzhen TargetRx, Inc.
    Inventors: Yihan Wang, Huanyin Li
  • Publication number: 20200240245
    Abstract: A blockage removal and permeability enhancement method for coalbed methane wells by using electric pulses is applicable to high-efficiency exploitation of coalbed methane wells.
    Type: Application
    Filed: June 26, 2017
    Publication date: July 30, 2020
    Applicant: CHINA UNIVERSITY OF MINING AND TECHNOLOGY
    Inventors: Bai quan LIN, Yihan WANG, Fazhi YAN, Xiangliang ZHANG